TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15860385
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin daily (group A, n = 20)
Study: 9790003
Drug: Midazolam (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.35 mg/kg) and ketamine (5 mg/kg) (Group A)
Study: 9790003
Drug: Trimeprazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimeprazine (3 mg/kg) and methadone (0.2 mg/kg) (Group B)
Study: 2551537
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin) for 5-10 days
Study: 2551537
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (continuous intravenous heparin)
Study: 3091459
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin)
Study: 31129183
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg zinc gluconate daily for 8 weeks)
Study: 19581455
Drug: IV doripenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV doripenem at 500 mg every 8 hours (q8h)
Study: 19581455
Drug: IV levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV levofloxacin at 250 mg every 24 hours (q24h)
Study: 11772847
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg intravenously)
Study: 9445204
Drug: Maximum dose
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum dose of acetazolamide (Diamox)
Study: 9445204
Drug: Small doses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doses of acetazolamide added to dorzolamide treatment
Study: 8010458
Drug: Demand dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand dose PCEA (3 mL; lockout interval = 10 min)
Study: 8010458
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion plus demand dose PCEA (3 mL/h and 6 mL/h)
Study: 8010458
Drug: Fixed-rate continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-rate continuous epidural infusion (CEI) at 12 mL/h
Study: 8010458
Drug: All PCEA
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All PCEA groups (including demand dose and continuous infusion)
Study: 8010458
Drug: PCEA groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA groups receiving no background infusion or a 3-mL/h background infusion
Study: 2644828
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 to 90 mg per day)
Study: 6366561
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg per day)
Study: 31860911
Drug: Pink-neck implant
Normalized name: chlorhexidine acetate Topical Solution [Steripod Pink]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pink-neck implant and abutment
Study: 31860911
Drug: Gray implant
Normalized name: gray birch pollen extract
DrugBank: Betula populifolia pollen (DB10724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gray implant and abutment (control)
Study: 28840583
Drug: G‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (5 μg/kg/day, for 6 consecutive days) in addition to standard medical therapy with antiviral drugs
Study: 28840583
Drug: Antiviral drugs
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drugs alone
Study: 25573908
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil plus pulse oral dexamethasone
Study: 18537470
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein Group (protein drink with additional protein and ginger twice daily)
Study: 18537470
Drug: Protein Group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein Group (protein drink and ginger twice daily)
Study: 15695544
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural local anaesthetic and steroid treatment
Study: 15695544
Drug: Targeted epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted epidural local anaesthetic and steroid placement with spinal endoscope
Study: 9895342
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine therapy (11, 22, and 44 mg daily)
Study: 7769051
Drug: Nafarelin 200
Normalized name: nafarelin 200 MCG/ACTUAT Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin 200 micrograms twice daily
Study: 7769051
Drug: Buserelin 200
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin 200 micrograms five times daily
Study: 7769051
Drug: Nafarelin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin 400 micrograms twice daily
Study: 7769051
Drug: Nafarelin (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (either dose)
Study: 282999
Drug: Sorbitol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (20 g of chocolate with sorbitol)
Study: 282999
Drug: Sucrose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (20 g of chocolate with 40% sucrose)
Study: 24094613
Drug: On-site group
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site group cognitive behavioral therapy (CBT) for depression
Study: 24094613
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care residential treatment
Study: 23739435
Drug: Cavinton (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton (25 mg intravenous during 10 days and then 10 mg 3 times daily during 3 months)
Study: 18415093
Drug: Artesunate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4 mg/kg)
Study: 18415093
Drug: Amodiaquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (10 mg/kg)
Study: 18415093
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Artesunate and Amodiaquine
Study: 16192502
Drug: MV with
Normalized name: MV with iron,folic acid(=,>1 mg)calcium (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MV with Vt = 10 mL/kg
Study: 16192502
Drug: MV with
Normalized name: MV with iron,folic acid(=,>1 mg)calcium (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MV with Vt = 5 mL/kg
Study: 15669893
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg/day
Study: 10856673
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g every 12 hours
Study: 10856673
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g every 24 hours
Study: 9118847
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving AED monotherapy
Study: 9118847
Drug: Current AED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current AED therapy
Study: 3541427
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (two doses: one at birth and another 2 months later, plus a booster at 12 months)
Study: 3541427
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (booster dose at 12 months)
Study: 3541427
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (two doses)
Study: 29672897
Drug: PF-04965842 3
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04965842 3 mg
Study: 29672897
Drug: PF-04965842 10
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-04965842 10 mg
Study: 29672897
Drug: PF-04965842 30
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 30 mg
Study: 29672897
Drug: PF-04965842 100
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 100 mg
Study: 29672897
Drug: PF-04965842 200
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-04965842 200 mg
Study: 29672897
Drug: PF-04965842 400
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 400 mg
Study: 29672897
Drug: PF-04965842 800
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 800 mg
Study: 29672897
Drug: PF-04965842 30
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 30 mg QD for 10 days
Study: 29672897
Drug: PF-04965842 100
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 100 mg QD for 10 days
Study: 29672897
Drug: PF-04965842 200
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-04965842 200 mg QD for 10 days
Study: 29672897
Drug: PF-04965842 400
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 400 mg QD for 10 days
Study: 29672897
Drug: PF-04965842 100
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 100 mg BID for 10 days
Study: 29672897
Drug: PF-04965842 200
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-04965842 200 mg BID for 10 days
Study: 26035523
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 to 450 mg/d)
Study: 26995811
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) integrated with dental treatment
Study: 26995811
Drug: Adapted dental
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted dental treatment
Study: 15752945
Drug: Losartan low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Losartan low-dose (2.5/5.0 mg)
Study: 15752945
Drug: Losartan middle-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan middle-dose (25/50 mg)
Study: 15752945
Drug: Losartan high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan high-dose (50/100 mg)
Study: 15752945
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from middle-dose losartan to placebo
Study: 15752945
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from high-dose losartan to placebo
Study: 15752945
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from low-dose losartan to placebo
Study: 10375429
Drug: Elastoviscous 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastoviscous 0.1% Hylan A solution
Study: 1464864
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids (3.8 g of eicosapentaenoic acid plus 2.0 g of docosahexaenoic acid) and naproxen (750 mg/day for 16 weeks)
Study: 1464864
Drug: corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn oil (placebo omega-3 fatty acids, 7 g/day for 16 weeks) and naproxen (750 mg/day for 10 weeks followed by stepwise reduction)
Study: 27854314
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (150 mg polyphenols)
Study: 19130903
Drug: Uterosacral vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral vaginal vault suspension
Study: 15001605
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily (group 1)
Study: 15001605
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg twice weekly (group 2)
Study: 15001605
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily (group 3)
Study: 12959308
Drug: Piroximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroximone (0.5 mg kg(‐1); n = 10)
Study: 12959308
Drug: Enoximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.5 mg kg(‐1); n = 10)
Study: 1107883
Drug: Propranolol 120
Normalized name: propranolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 120 mg daily
Study: 2885116
Drug: Chlordesmethyldiazepam 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam 2 mg daily
Study: 25234550
Drug: 2-mg test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg test tablet
Study: 9725476
Drug: Test tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablet
Study: 23800419
Drug: Imipramine (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (targeted dose adjusted to 200-300 ng/ml)
Study: 23800419
Drug: Venlafaxine (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (high-dose, increased to 300-375 mg/day)
Study: 18401987
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia using intravenous or inhaled anesthesia, maintenance with sevoflurane in oxygen and air at variable concentrations to maintain a bispectral index (BIS) between 40 and 60.
Study: 19907420
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg of the ampakine CX717
Study: 19907420
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg of naloxone
Study: 16358864
Drug: Antibiotics (cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefuroxime axetil, clarithromycin) and steroid (prednisone)
Study: 16358864
Drug: Antibiotics (cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefuroxime axetil, clarithromycin)
Study: 12148574
Drug: Ifosfamide by
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide by a 24-hour infusion on day 1
Study: 12148574
Drug: Ifosfamide by
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide by a 3-hour infusion on days 1-4
Study: 8307444
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg or 40 mg) for 5.7 weeks
Study: 8307444
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prior antisecretory treatment)
Study: 8307444
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg or 40 mg)
Study: 6402051
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose (D5W) infusion
Study: 18552701
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (Group B, n = 113)
Study: 15776337
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group restricted to daily activities
Study: 7782057
Drug: Purified urinary
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified urinary follicle‐stimulating hormone (uFSH‐HP; Metrodin HP®) in standard IVF
Study: 7782057
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pure FSH and human menopausal gonadotrophin (hMG; Pergonal®) in standard IVF
Study: 31442498
Drug: Optimal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal therapy (predicted)
Study: 31442498
Drug: Actual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual therapy received
Study: 24507657
Drug: TRO40303 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO40303 (0.5 to 13 mg/kg)
Study: 20676646
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate injection (SH)
Study: 20676646
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy modalities (PTM)
Study: 20179559
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.2 mg/kg)
Study: 17331930
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL 6% hydroxyethyl starch (HES)
Study: 17331930
Drug: 1500 mL
Normalized name: Bag/Pump Set 1500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mL lactated Ringer's (LR)
Study: 7846196
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg IV as a 3-min infusion
Study: 7846196
Drug: Zolpidem 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 20 mg orally
Study: 7846196
Drug: Zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5 mg IV
Study: 7846196
Drug: Zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5 mg orally
Study: 1204500
Drug: Attenuated influenza-A-virus
Normalized name: influenza A virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated influenza-A-virus strain 'Alice' (H3N2), given intransally in drops (10(7,2) ID50 per dose), twice seven days apart
Study: 1204500
Drug: Inactivated virus
Normalized name: covid-19, inactivated virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated virus vaccine
Study: 28301620
Drug: CeraVe Itch
Normalized name: CeraVe itch Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: CeraVe Itch Relief Lotion and Cream (1% pramoxine hydroxide)
Study: 28301620
Drug: CeraVe Itch
Normalized name: CeraVe itch Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: CeraVe Itch Relief Cream (1% pramoxine hydrochloride)
Study: 28301620
Drug: CeraVe Itch
Normalized name: CeraVe itch Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: CeraVe Itch Relief Cream (1% pramoxine hydrochloride) used daily over 6 days
Study: 23329885
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 2.4 grams daily
Study: 16397287
Drug: Sirolimus tablet
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus tablet
Study: 16397287
Drug: Sirolimus solution
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus solution
Study: 9170048
Drug: Breath-holding after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath-holding after O2 administration
Study: 3536677
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole 500 mg eight hourly (19 patients)
Study: 3536677
Drug: Identical intravenous
Normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical intravenous placebo (20 patients)
Study: 3536677
Drug: Identical intravenous
Normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical intravenous placebo
Study: 27097575
Drug: Budesonide suspension
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide suspension
Study: 27097575
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no regular inhalation of corticosteroid)
Study: 8594515
Drug: Brovincamine fumarate
Normalized name: vincamine
DrugBank: Vincamine (DB13374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brovincamine fumarate (20 mg 3 times daily)
Study: 18707726
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times daily)
Study: 6961759
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg daily
Study: 3907824
Drug: Metoclopramide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 60 mg
Study: 3907824
Drug: Metoclopramide 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 120 mg
Study: 29850782
Drug: Valsartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine combination therapy (80/5 mg) for 16 weeks
Study: 22789773
Drug: Video-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-based therapy at home for patients with stroke (3 months duration)
Study: 22789773
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (weekly outpatient therapy sessions)
Study: 3354802
Drug: Caudal injection
Normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal injection of 1 ml/kg bupivacaine 0.25%
Study: 3354802
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration of 0.5 ml/kg bupivacaine 0.25%
Study: 27486141
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24-48 IU/day)
Study: 25136015
Drug: GSK1322322 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 at 1,500 mg b.i.d.
Study: 25136015
Drug: Linezolid at
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid at 600 mg b.i.d.
Study: 23174463
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy group (IPT-G)